Dexamethasone induces aberrant macrophage immune function and apoptosis

Area of Science:

• Immunology
• Molecular Biology
• Pharmacology

Background:

• Glucocorticoids (GCs) are potent clinical drugs with complex mechanisms of action.
• Macrophages are key targets of GCs and play a controversial role in tumor immunity.
• The precise molecular pathways linking GCs, macrophages, and tumor immunity require further elucidation.

Purpose of the Study:

• To investigate the role of transcription factor Krüppel-like factor 9 (KLF9) in mediating the effects of GCs on macrophages.
• To determine the impact of KLF9 modulation on macrophage apoptosis, inflammatory responses, and tumor cell survival.
• To explore KLF9 as a potential therapeutic target for modulating GC activity in cancer.

Main Methods:

• Utilized a lentivirus system for overexpression and knockdown of KLF9 in RAW 264.7 macrophage cells.
• Assessed dexamethasone (Dex)-induced reactive oxygen species (ROS) generation and mitochondrial apoptosis.
• Employed ELISA assays to measure cyclooxygenase-2 (COX-2) expression, prostaglandin E2, and pro-inflammatory cytokine secretion.
• Established a co-culture system to evaluate the effect of KLF9-overexpressing macrophages on HepG2 cell survival.

Main Results:

• Dexamethasone induced ROS generation and mitochondria-dependent apoptosis in RAW 264.7 cells, mediated by KLF9.
• Overexpression of KLF9 significantly enhanced apoptosis in RAW 264.7 cells.
• Increased KLF9 expression inhibited lipopolysaccharide (LPS)-induced COX-2 expression and reduced prostaglandin E2 and pro-inflammatory cytokine release.
• Overexpression of KLF9 in macrophages promoted HepG2 cell survival in a co-culture system.

Conclusions:

• KLF9 promotes apoptosis of pro-inflammatory macrophages.
• KLF9 suppresses the antitumor effects mediated by macrophages.
• GCs may target KLF9 as a novel mechanism to suppress antineoplastic activity, highlighting its potential as a therapeutic target.